NCT03929705 (IQ) is a clinical trial in Tuberculosis (TB), sponsored by Oxford Immunotec.

Who is sponsoring NCT03929705?

NCT03929705 is sponsored by Oxford Immunotec.

What condition does NCT03929705 study?

NCT03929705 studies Tuberculosis (TB).

Is NCT03929705 still recruiting?

NCT03929705 is currently completed. Last updated 23 October 2020.

Last reviewed 2020-10-23 · How we verify

NCT03929705: IQ

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Assessing the Ability of the T-SPOT®.TB Test

Completed Last updated 23 October 2020

What this trial tests

trial in Tuberculosis (TB) in 676 participants. Completed in 23 January 2020.

Timeline

2 May 2019

Primary endpoint
23 January 2020

23 January 2020

Quick facts

Lead sponsor	Oxford Immunotec
Status	Completed
Study type	OBSERVATIONAL
Enrollment	676
Start date	2 May 2019
Primary completion	23 January 2020
Estimated completion	23 January 2020
Sites	1 location across South Africa

Conditions studied

Tuberculosis (TB) — all drugs for Tuberculosis (TB) →

Sponsor

Oxford Immunotec

Who can join

18 and older, any sex, with Tuberculosis (TB). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of this clinical research study is to demonstrate performance of the normalized TB specific lymphocyte response in identifying patients with active TB disease. The secondary exploratory objective is to demonstrate that active TB cannot be identified using an antigen-to-mitogen ratio derived from an ELISA-based IGRA.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Tuberculosis (TB)

Currently open trials in the same condition.

NCT06963606 — Effectiveness of Computer-Aided Detection Chest X-Ray Screening for Improving Tuberculosis Diagnostic Yield in Chinese P · NA · recruiting
NCT07178860 — Respiratory Health and Wellbeing Post Pulmonary Tuberculosis · recruiting
NCT06909799 — A Confirmatory Trial of Adjunctive NAC to Prevent Post Tuberculosis Lung Disease · NA · recruiting
NCT06997367 — Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine MTBVAC in Healthy Indian Adults and Adolescents (BBV16 · Phase 2 · active not recruiting
NCT06916962 — Examining Psycho-Socioeconomic Linkages in TB Care: The UPLIFT Trial · NA · recruiting

Other Oxford Immunotec trials

Trials by the same sponsor.

NCT04141982 — Clinical Concordance Evaluation of T-SPOT®.TB Assay Performance (T-Cell SelectTM Study) · completed
NCT03973970 — Assessing the Ability of the T-SPOT®.TB Test (IQ) · completed
NCT03201042 — Lyme Test Indication Combinations (LyTIC) Study · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03929705 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Oxford Immunotec
Last refreshed: 23 October 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03929705.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing